Trulieve Cannabis (TRLV) Stock Overview
Operates as a cannabis retailer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TRLV Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trulieve Cannabis Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.62 |
| 52 Week High | US$13.28 |
| 52 Week Low | US$4.62 |
| Beta | 1.76 |
| 1 Month Change | 20.41% |
| 3 Month Change | 23.62% |
| 1 Year Change | 72.40% |
| 3 Year Change | 60.28% |
| 5 Year Change | -52.76% |
| Change since IPO | -0.47% |
Recent News & Updates
Seeking Alpha • Sep 11
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking Alpha
Narrative Update • Aug 13
TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.
New Narrative • Aug 11
Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?Recent updates
Seeking Alpha • Sep 11
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking AlphaNarrative Update • Aug 13
TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.New Narrative • Aug 11
Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?
Narrative Update • Jul 30
TRLV: Federal Rescheduling And Georgia Expansion Will Drive Future Upside
Analysts have adjusted their fair value estimate for Trulieve Cannabis from $17.25 to $15.00, citing updated assumptions on revenue trends, profit margins, and future P/E that align with recent Street research and a new $15 price target. Analyst Commentary Recent Street research on Trulieve Cannabis emphasizes both the potential upside tied to regulatory shifts and the risks that could keep the stock under pressure.Narrative Update • Jul 16
TRLV: Georgia Expansion And Schedule III Pathway Will Support Future Upside
Analysts have raised their price target on Trulieve Cannabis to $17.25 from $14.08, citing updated assumptions around profit margin, P/E expectations, and other valuation drivers. What’s in the News for Trulieve Cannabis Trulieve Cannabis marked the expansion of Georgia’s medical cannabis program with a ceremonial first sale at its Marietta dispensary under the new "Putting Georgia's Patients First Act." The act allows flower and vaporization products for patients aged 21 and older and broadens qualifying conditions such as lupus, HIV, and inflammatory bowel disease (source: company announcement).New Narrative • Jul 02
Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a vertically integrated cannabis business focused primarily on medical patients across several U.S. states. What are the underlying business or industry changes driving this perspective?Narrative Update • Jun 26
TRLV: NYSE Listing And Buybacks Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Trulieve Cannabis from $21.00 to approximately $19.42, citing updated assumptions about long-term profit margins and a slightly lower future P/E multiple. What’s in the News for Trulieve Cannabis Trulieve Cannabis listed on the New York Stock Exchange under the ticker TRLV, becoming the first U.S. based marijuana company on the NYSE after a federal rescheduling of medical marijuana to Schedule III, according to recent news coverage.Analysis Article • Jun 21
Trulieve Cannabis (TRLV) Stock Could Be 51.9% Undervalued After NYSE Listing
Trulieve Cannabis (TRLV) has become the first U.S. marijuana company to trade on the New York Stock Exchange, following the federal reclassification of medical marijuana, which opened the door to its uplisting. See our latest analysis for Trulieve Cannabis. The recent NYSE listing comes after a 34.67% 1 month share price return and a 58.56% 3 month share price return. The 1 year total shareholder return of 193.08% and 3 year total shareholder return of 155.70% contrast with a 5 year total...New Narrative • Jun 11
Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator
Catalysts About Trulieve Cannabis Trulieve Cannabis operates cannabis cultivation, production and retail operations serving primarily medical patients across multiple U.S. states. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| TRLV | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.0% | -3.4% | -0.9% |
| 1Y | 72.4% | 45.9% | 13.9% |
Return vs Industry: TRLV exceeded the US Pharmaceuticals industry which returned 45.9% over the past year.
Return vs Market: TRLV exceeded the US Market which returned 13.9% over the past year.
Price Volatility
| TRLV volatility | |
|---|---|
| TRLV Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TRLV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TRLV's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands.
Trulieve Cannabis Corp. Fundamentals Summary
| TRLV fundamental statistics | |
|---|---|
| Market cap | US$2.18b |
| Earnings (TTM) | -US$467.83m |
| Revenue (TTM) | US$1.14b |
2.0x
P/S Ratio-4.8x
P/E RatioIs TRLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRLV income statement (TTM) | |
|---|---|
| Revenue | US$1.14b |
| Cost of Revenue | US$461.65m |
| Gross Profit | US$677.39m |
| Other Expenses | US$1.15b |
| Earnings | -US$467.83m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | 59.47% |
| Net Profit Margin | -41.07% |
| Debt/Equity Ratio | 37.9% |
How did TRLV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 21:42 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trulieve Cannabis Corp. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Matt Bottomley | Canaccord Genuity |